Tekmira Awarded Up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus
VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 15, 2010) - Tekmira Pharmaceuticals Corporation (TSX:TKM - News), a leader in RNA interference (RNAi) therapeutics, today announced that it has been awarded a new contract with the United States Department of Defense (DoD) Chemical and Biological Defense Program (CBDP) through the U.S. Army Space and Missile Defense Command (SMDC), to advance an RNAi therapeutic utilizing Tekmira's lipid nanoparticle technology, SNALP (stable nucleic acid-lipid particle), to treat Ebola virus infection, which is lethal to humans. More than 15% of the estimated value of this award will be subcontracted to U.S. businesses. Tekmira has a U.S. affiliated office based in Washington state, Protiva USA.
Tekmira Nails $140M Defense Contract to Make RNAi Drug for Ebola
.........Tekmira won the contract two months after it published results in The Lancet which showed that its RNAi candidate was able to offer 100 percent protection to primates who were exposed to an otherwise lethal dose of Ebola virus.